U.S. patent application number 13/255705 was filed with the patent office on 2012-01-05 for use of rosuvastatin lactols as medicaments.
This patent application is currently assigned to Bradford Pharma Limited. Invention is credited to Peter Jackson, Derek Lindsay.
Application Number | 20120004408 13/255705 |
Document ID | / |
Family ID | 40600801 |
Filed Date | 2012-01-05 |
United States Patent
Application |
20120004408 |
Kind Code |
A1 |
Lindsay; Derek ; et
al. |
January 5, 2012 |
Use of Rosuvastatin Lactols as Medicaments
Abstract
This invention relates to the discovery of novel rosuvastatin
analogues. More specifically, the invention relates to novel
rosuvastatin analogues which have utility in treating conditions
treatable by the inhibition of HMG-CoA reductase.
Inventors: |
Lindsay; Derek; (Wigan,
GB) ; Jackson; Peter; (Wigan, GB) |
Assignee: |
Bradford Pharma Limited
|
Family ID: |
40600801 |
Appl. No.: |
13/255705 |
Filed: |
March 10, 2010 |
PCT Filed: |
March 10, 2010 |
PCT NO: |
PCT/GB2010/050409 |
371 Date: |
September 9, 2011 |
Current U.S.
Class: |
544/297 |
Current CPC
Class: |
A61P 25/00 20180101;
A61P 29/00 20180101; A61P 3/06 20180101; A61P 9/10 20180101; A61P
25/28 20180101; A61P 43/00 20180101; A61P 9/00 20180101; A61P 35/00
20180101; A61P 3/00 20180101; C07D 405/06 20130101; A61P 3/10
20180101; A61K 31/505 20130101; C07D 405/14 20130101; A61P 9/12
20180101; A61P 27/12 20180101 |
Class at
Publication: |
544/297 |
International
Class: |
C07D 405/14 20060101
C07D405/14; C07D 405/06 20060101 C07D405/06 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 10, 2009 |
GB |
09041005 |
Claims
1. A compound of Formula I and pharmaceutically acceptable salts
and solvates thereof: ##STR00018## for use in treating a condition
treatable by the inhibition of the enzyme
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase), wherein condition treatable by the inhibition of
HMG-CoA reductase is selected from the group consisting of:
hypercholesterolemia, atherosclerosis, hyperlipidemia,
cardiovascular disease, coronary heart disease, myocardial
infarction, stroke, peripheral artery disease, inflammation,
dementia, cancer, nuclear cataracts, diabetes and hypertension,
further wherein: R.sup.1 and R.sup.4 are independently selected
from the group consisting of: hydrogen, halo, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-4 alkyl
aryl, heterocyclyl, and C.sub.1-4 alkyl heteroaryl; R.sup.2 is
--S(O).sub.2R.sup.9 wherein R.sup.9 is C.sub.1-6 alkyl, C.sub.3-6
cycloalkyl, C.sub.1-6 alkyl aryl or aryl; R.sup.3 is hydrogen,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or aryl;
R.sup.5 and R.sup.6 are independently selected from the group
consisting of: hydrogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl,
C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-6 alkyl
aryl, C.sub.1-6 alkanoyl aryl, heteroaryl, C.sub.1-6 alkanoyl
heteroaryl and C.sub.1-6 alkyl heteroaryl; provided always that
both R.sup.5 and R.sup.6 are not hydrogen; R.sup.7 and R.sup.8 are
independently selected from the group consisting of: H, C.sub.1-4
alkyl and halo; X is
--(CR.sup.aR.sup.b).sub.m(CR.sup.a.dbd.CR.sup.b).sub.n(CR.sup.aR.sup.b).s-
ub.o where R.sup.a and R.sup.b are independently selected from the
group consisting of: H, methyl, ethyl and halo and m, n, and o are
independently 0, 1, 2, or 3 provided that m+n+o is not more than 3;
and wherein each of the above groups R.sup.1 to R.sup.9 may, where
chemically possible, be independently optionally substituted by
from 1 to 5 groups chosen independently at each occurrence from the
groups comprising: halo, C.sub.1-3 alkyl, halo C.sub.1-3 alkyl,
C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, hydroxy, and cyano.
2. A compound of claim 1, wherein R.sup.1 is C.sub.1-6 alkyl.
3. A compound of claim 1, wherein R.sup.2--S(O).sub.2R.sup.9
wherein R.sup.9 is C.sub.1-6 alkyl.
4. A compound of claim 1, wherein R.sup.3 is hydrogen or C.sub.1-6
alkyl.
5. A compound of claim 1, wherein R.sup.4 is optionally substituted
aryl.
6. A compound of claim 1, wherein R.sup.1 is i-propyl, R.sup.2 is
--S(O).sub.2Me, R.sup.3 is methyl and R.sup.4 4-fluorophenyl.
7. A compound of claim 1, wherein R.sup.5 is selected from the
group consisting of: hydrogen, C.sub.1-6 alkyl, aryl, C.sub.1-6
alkyl aryl, C.sub.1-6 alkanoyl aryl, heteroaryl, C.sub.1-6 alkanoyl
heteroaryl and C.sub.1-6 alkyl heteroaryl.
8. A compound of claim 7, wherein R.sup.5 is hydrogen.
9. A compound of claim 7, wherein R.sup.5 is selected from the
group consisting of: --C.sub.1 alkyl-Ph, --C.sub.2 alkyl-Ph,
--C.sub.3 alkyl-Ph, and --C.sub.4 alkyl-Ph.
10. A compound of claim 9, wherein R.sup.5 is benzyl.
11. A compound of claim 7, wherein R.sup.5 is C.sub.1-6alkanoyl
pyridine.
12. A compound of claim 11, wherein R.sup.5 is 3-methanoyl
pyridine.
13. A compound of claim 1, wherein R.sup.6 is selected from the
group consisting of: hydrogen, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-6
alkyl aryl, heteroaryl and C.sub.1-6 alkyl heteroaryl.
14. A compound of claim 13, wherein R.sup.6 is selected from the
group consisting of: C.sub.1-6 alkyl, C.sub.1-6 haloalkyl and
C.sub.2-6 alkenyl.
15. A compound of claim 14 wherein R.sup.6 is selected from the
group consisting of: methyl, ethyl, propyl, butyl, chloromethyl,
chloroethyl, chloropropyl, chlorobutyl and propylene.
16. A compound of claim 13, wherein R.sup.6 is optionally
substituted aryl.
17. A compound of claim 16, wherein R.sup.6 is selected from the
group consisting of: C.sub.1-6 alkoxy substituted phenyl and halo
substituted phenyl.
18. A compound of claim 16, wherein R.sup.6 is selected from the
group consisting of: 2,4,6-trifluorophenyl and
2,4-dimethoxyphenyl.
19. A compound of claim 1, wherein R.sup.5 is hydrogen and R.sup.6
is an optionally substituted aromatic group.
20. A compound of claim 1, wherein R.sup.5 is an optionally
substituted benzyl and R.sup.6 is an optionally substituted
C.sub.1-6alkyl, an optionally substituted C.sub.2-6 alkenyl or a
C.sub.1-6 haloalkyl.
21. A compound of claim 1, wherein R.sup.5 is a C.sub.1-6 alkanoyl
heteroaryl and R.sup.6 is an optionally substituted
C.sub.1-6alkyl.
22. A compound of claim 1, wherein R.sup.7 is H and R.sup.8 is
H.
23. A compound of claim 1, wherein R.sup.a is H, R.sup.b is H and
m=0, n=1 and o=0.
24. A compound of claim 1 which has a structure selected from:
##STR00019## ##STR00020## ##STR00021##
25-27. (canceled)
Description
[0001] The present invention relates to rosuvastatin lactols. In
particular, the present invention relates to the use of
rosuvastatin lactols in the manufacture of a medicament for
treating certain conditions. Conditions that are treatable using
the compounds of the present invention include conditions which are
modulated by the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (HMG-CoA reductase). Inhibition of the enzyme therefore
represents a viable therapy for a number of diseases. The compounds
used in the invention are 6-(3- or 4-carboxamido-substituted
pyrrol-1-yl)-4-hydroxy-3,5-dihydro-pyran-2-ol derivatives.
[0002] Rosuvastatin,
7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-p-
yrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid, and its use in the
inhibition of the biosynthesis of cholesterol was first disclosed
in EP 0521471. Rosuvastatin is a potent inhibitor of HMG-CoA
enzyme.
[0003] Clin Invest Med, Volume 24, No 5, p 258-72, 2001 (Baker and
Tamopolsky) discloses that whilst statins having an open, hydroxy
acid conformation are active, the lactone, closed-ring analogue is
inactive. Hepatic hydrolysis at alkaline pH decyclises and hence
activates the lactone prodrugs lovastatin and simvastatin in vivo.
However, one problem with such compounds is that extensive first
path metabolism leads to rapid clearance of these statins.
[0004] Similarly, Trends in Pharmacological Sciences, Volume 19,
Issue 1, 1 Jan. 1998, Pages 26-37 discloses that the inactive
lactones must be metabolised to their corresponding open hydroxy
acid forms in order to inhibit HMG-CoA reductase in the manner that
rosuvastatin does.
[0005] The lactone form, and also the ring opened active form, may
suffer problems in terms of stability over an extended period of
time. This represents a significant problem during manufacture of
an active principal or during extended storage of the same in a
pharmacy. For example, loss of the hydroxy group in a dehydration
reaction may occur. The resulting decomposition product may have a
double bond that is conjugated with the lactone carbonyl group and
this will tend to favour the potential decomposition product.
Equally, in the ring opened form, one of the possible decomposition
products could also have a conjugated double bond with the acid
carbonyl group.
[0006] It is therefore an aim of the present invention to provide
compounds capable of inhibiting HMG-CoA reductase. Rosuvastatin is
a very potent inhibitor of HMG-CoA reductase. It is also therefore
an aim of the present invention to provide compounds capable of
inhibiting HMG-CoA reductase which have an IC50 value comparable to
or better than that of rosuvastatin. Ideally, these compounds will
have good stability and bioavailability relative to rosuvastatin.
It is thus an aim to provide compounds having improved stability.
Ideally, the compounds will have an extended shelf-life. It is thus
an aim of the present invention to provide compounds capable of
inhibiting HMG-CoA reductase which have increased half-life. It is
thus an aim of the present invention to provide further compounds
capable of inhibiting HMG-CoA reductase and having improved
bioavailability. It is also an aim of the present invention to
provide compounds capable of inhibiting HMG-CoA reductase and
increasing promotion of high density lipoprotein (HDL). It is also
an aim of the present invention to provide compounds capable of
reducing low density lipoprotein (LDL) and increasing promotion of
high density lipoprotein (HDL). Specifically, it is an aim of the
present invention to provide compounds capable of reducing low
density lipoprotein (LDL) and increasing promotion of high density
lipoprotein (HDL) by more than 10%, preferably up to 15% or higher.
The invention thus seeks to provide therapies for inhibiting
cholesterol biosynthesis. The invention also aims to treat a range
of diseases in which cholesterol formation is inhibited.
[0007] This invention provides compounds that achieve one or more
of the above aims.
[0008] According to one aspect, the present invention provides a
use of a compound of Formula I and pharmaceutically acceptable
salts and solvates thereof:
##STR00001##
in the manufacture of a medicament for treating a condition
treatable by the inhibition of the enzyme
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase), wherein: R.sup.1 and R.sup.4 are independently selected
from the group comprising: hydrogen, halo, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-4 alkyl
aryl, heterocyclyl, and C.sub.1-4 alkyl heteroaryl; R.sup.2 is
--S(O).sub.2R.sup.9 wherein R.sup.9 is C.sub.1-6 alkyl, C.sub.3-6
cycloalkyl, C.sub.1-6 alkyl aryl or aryl; R.sup.3 is hydrogen,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or aryl;
R.sup.5 and R.sup.6 are independently selected from the group
comprising: hydrogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl,
C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-6 alkyl
aryl, C.sub.1-6alkanoyl aryl, heteroaryl, C.sub.1-6alkanoyl
heteroaryl and C.sub.1-6 alkyl heteroaryl; provided always that
both R.sup.5 and R.sup.6 are not hydrogen; R.sup.7 and R.sup.8 are
independently selected from the group comprising: H, C.sub.1-4
alkyl and halo; X is
--(CR.sup.aR.sup.b).sub.m(CR.sup.a.dbd.CR.sup.b).sub.n(CR.sup.aR.sup.b).s-
ub.o where R.sup.a and R.sup.b are independently selected from the
group comprising: H, methyl, ethyl and halo and m, n, and o are
independently 0, 1, 2, or 3 provided that m+n+o is not more than 3;
and wherein each of the above groups R.sup.1 to R.sup.9 may, where
chemically possible, be independently optionally substituted by
from 1 to 5 groups chosen independently at each occurrence from the
groups comprising: halo, C.sub.1-3 alkyl, halo C.sub.1-3 alkyl,
C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, hydroxy, and cyano.
[0009] Usually conditions that are modulated by HMG-CoA reductase
are conditions that would be treated by the inhibition of the
enzyme using a compound of the present invention.
[0010] According to another aspect, the present invention provides
a compound of Formula I and pharmaceutically acceptable salts and
solvates thereof:
##STR00002##
for use in treating a condition treatable by the inhibition of the
enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase) wherein R.sup.1-R.sup.9, R.sup.a, R.sup.b, X, m, n and o
are as defined above.
[0011] According to another aspect, the present invention provides
a method of treating a condition treatable by the inhibition of the
enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA
reductase) comprising administering an effective amount of a
compound of Formula I:
##STR00003##
or a pharmaceutically acceptable salt or solvate thereof, wherein
R.sup.1-R.sup.9, R.sup.a, R.sup.b, X, m, n and o are as defined
above.
[0012] The compounds of the invention may have activity in their
own right or may in certain cases ring open under physiological
conditions to corresponding compounds having inhibitory
activity.
[0013] Reference is made to the accompanying figure (FIG. 1) which
illustrates the effect on the level of plasma triglycerides in rats
after administration of rosuvastatin (25 mg/kg po) and four
rosuvastatin analogues (25 mg/kg).
[0014] Pharmaceutically acceptable salts of the compounds of
formula (I) include the acid addition and base salts thereof.
[0015] Suitable acid addition salts are formed from acids which
form non-toxic salts. Examples include the acetate, aspartate,
benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate,
borate, camsylate, citrate, edisylate, esylate, formate, fumarate,
gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate,
hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide,
isethionate, lactate, malate, maleate, malonate, mesylate,
methylsulphate, naphthylate, 1,5-naphthalenedisulfonate,
2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate,
pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate,
saccharate, stearate, succinate, tartrate, tosylate and
trifluoroacetate salts.
[0016] Suitable base salts are formed from bases which form
non-toxic salts. Examples include the aluminium, arginine,
benzathine, calcium, choline, diethylamine, diolamine, glycine,
lysine, magnesium, meglumine, olamine, potassium, sodium,
tromethamine and zinc salts. Hemisalts of acids and bases may also
be formed, for example, hemisulphate and hemicalcium salts. For a
review on suitable salts, see "Handbook of Pharmaceutical Salts:
Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH,
Weinheim, Germany, 2002).
[0017] Pharmaceutically acceptable salts of compounds of formula
(I) may be prepared by one or more of three methods: [0018] (i) by
reacting the compound of formula (I) with the desired acid or base;
[0019] (ii) by removing an acid- or base-labile protecting group
from a suitable precursor of the compound of formula (I) or by
ring-opening a suitable cyclic precursor, for example, a lactone or
lactam, using the desired acid or base; or [0020] (iii) by
converting one salt of the compound of formula (I) to another by
reaction with an appropriate acid or base or by means of a suitable
ion exchange column.
[0021] All three reactions are typically carried out in solution.
The resulting salt may precipitate out and be collected by
filtration or may be recovered by evaporation of the solvent. The
degree of ionisation in the resulting salt may vary from completely
ionised to almost non-ionised.
[0022] The compounds of the invention may exist in both unsolvated
and solvated forms. The term `solvate` is used herein to describe a
molecular complex comprising the compound of the invention and a
stoichiometric amount of one or more pharmaceutically acceptable
solvent molecules, for example, ethanol. The term `hydrate` is
employed when said solvent is water.
[0023] Included within the scope of the invention are complexes
such as clathrates, drug-host inclusion complexes wherein, in
contrast to the aforementioned solvates, the drug and host are
present in stoichiometric or non-stoichiometric amounts. Also
included are complexes of the drug containing two or more organic
and/or inorganic components which may be in stoichiometric or
non-stoichiometric amounts. The resulting complexes may be ionised,
partially ionised, or non-ionised. For a review of such complexes,
see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
[0024] Hereinafter all references to compounds of formula (I)
include references to salts, solvates and complexes thereof and to
solvates and complexes of salts thereof.
[0025] The compounds of the invention include compounds of formula
(I) as hereinbefore defined, including all polymorphs and crystal
habits thereof, prodrugs and isomers thereof (including optical,
geometric and tautomeric isomers) as hereinafter defined and
isotopically-labeled compounds of formula (I).
[0026] Before purification, the compounds of the present invention
may exist as a mixture of enantiomers depending on the synthetic
procedure used. For example, the compounds of the present invention
may exist as a mixture of enantiomers having a ratio of between 2:1
and 3:1, though they may also occur in other ratios. The
enantiomers can be separated by conventional techniques known in
the art. Thus the invention covers individual enantiomers as well
as mixtures thereof. When the chemical structures disclosed herein
includes an `*`, it is intended that the compound is a mixture of
enantiomers having a ratio of between 2:1 and 3:1.
[0027] For some of the steps of the process of preparation of the
compounds of formula (I), it may be necessary to protect potential
reactive functions that are not wished to react, and to cleave said
protecting groups in consequence. In such a case, any compatible
protecting radical can be used. In particular methods of protection
and deprotection such as those described by T. W. GREENE
(Protective Groups in Organic Synthesis, A. Wiley-Interscience
Publication, 1981) or by P. J. Kocienski (Protecting groups, Georg
Thieme Verlag, 1994), can be used. All of the above reactions and
the preparations of novel starting materials used in the preceding
methods are conventional and appropriate reagents and reaction
conditions for their performance or preparation as well as
procedures for isolating the desired products will be well-known to
those skilled in the art with reference to literature precedents
and the examples and preparations hereto.
[0028] Also, the compounds of formula (I) as well as intermediate
for the preparation thereof can be purified according to various
well-known methods, such as for example crystallization or
chromatography.
[0029] In an embodiment, R.sup.1 is selected from the group
comprising: hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or
C.sub.3-6 cycloalkyl. In an embodiment, R.sup.1 is selected from
the group comprising: C.sub.2-6 alkenyl or C.sub.3-6 cycloalkyl. In
an alternative embodiment, R.sup.1 is C.sub.1-6 alkyl. In an
embodiment, R.sup.1 is methyl, ethyl, propyl or butyl. In an
embodiment, R.sup.1 is i-propyl.
[0030] In an embodiment, R.sup.2 is --S(O).sub.2R.sup.9 wherein
R.sup.9 is C.sub.1-6 alkyl. In an embodiment, R.sup.2 is
--S(O).sub.2R.sup.9 wherein R.sup.9 is methyl, ethyl, propyl or
butyl. In an embodiment, R.sup.2 is --S(O).sub.2Me.
[0031] In an embodiment, R.sup.3 is selected from the group
comprising: hydrogen, C.sub.1-6 alkyl and C.sub.3-6 cycloalkyl. In
an embodiment, R.sup.3 is selected from the group comprising:
hydrogen and C.sub.1-6 alkyl. In an embodiment, R.sup.3 is methyl,
ethyl or propyl. In an embodiment, R.sup.3 is methyl.
[0032] In an embodiment, R.sup.4 is selected from the group
comprising: aryl, C.sub.1-4 alkyl aryl, heteroaryl and C.sub.1-4
alkyl heteroaryl, wherein each of the aforementioned groups may be
optionally substituted as discussed above in relation to the first
aspect. In an embodiment, R.sup.4 is selected from the group
comprising: aryl and C.sub.1-4 alkyl aryl. In an embodiment,
R.sup.4 is aryl. In an embodiment, R.sup.4 is phenyl. In an
embodiment, R.sup.4 is substituted with halo, preferably wherein
the halo is fluorine. In an embodiment, R.sup.4 is
4-fluorophenyl.
[0033] In an embodiment, R.sup.5 is selected from the group
comprising: hydrogen, C.sub.1-6 alkyl, aryl, C.sub.1-6 alkyl aryl,
C.sub.1-6alkanoyl aryl, heteroaryl, C.sub.1-6alkanoyl heteroaryl
and C.sub.1-6 alkyl heteroaryl. In an embodiment, R.sup.5 is
selected from the group comprising: hydrogen, C.sub.1-6 alkyl aryl,
C.sub.1-6alkanoyl aryl, C.sub.1-6 alkyl heteroaryl and
C.sub.1-6alkanoyl heteroaryl. In an embodiment, R.sup.5 is
hydrogen. In an alternative embodiment, R.sup.5 is C.sub.1-6 alkyl
aryl, e.g. --C.sub.1 alkyl-Ph, --C.sub.2 alkyl-Ph, --C.sub.3
alkyl-Ph, or --C.sub.4 alkyl-Ph. In an embodiment, R.sup.5 is
benzyl. In an alternative embodiment, R.sup.5 is C.sub.1-6alkanoyl
heteroaryl, e.g. --(C.dbd.O)-het, CH.sub.2--(C.dbd.O)-het or
(C.dbd.O)--CH.sub.2-het (wherein `het` is heteroaryl). In an
embodiment, R.sup.5 is C.sub.1-6alkanoyl pyridine, e.g. 2-methanoyl
pyridine, 3-methanoyl pyridine or 4-methanoyl pyridine, preferably
3-methanoyl pyridine.
[0034] In an embodiment, R.sup.6 is selected from the group
comprising: hydrogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl,
C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, aryl, C.sub.1-6 alkyl
aryl, heteroaryl and C.sub.1-6 alkyl heteroaryl. In an embodiment,
R.sup.6 is C.sub.1-6 alkyl. In an embodiment, R.sup.6 is methyl or
ethyl. In another embodiment, R.sup.6 is propyl or butyl. In an
embodiment, R.sup.6 is C.sub.1-6 haloalkyl, e.g. a C.sub.1-6
chloroalkyl such as chloromethyl, chloroethyl, chloropropyl or
chlorobutyl. In an embodiment, R.sup.6 is C.sub.2-6 alkenyl, e.g.
propylene. In an embodiment, R.sup.6 is optionally substituted aryl
e.g. C.sub.1-6alkoxy substituted phenyl or halo substituted phenyl.
In a preferred embodiment, R.sup.6 is 2,4,6-trifluorophenyl. In a
preferred embodiment, R.sup.6 is 2,4-dimethoxyphenyl.
[0035] In an embodiment, R.sup.7 is H.
[0036] In an embodiment, R.sup.8 is H.
[0037] In an embodiment, m=0. In an embodiment, o=0. In an
embodiment, n=1. In an embodiment, m=0, n=1 and o=0. In an
embodiment, m=1, n=1 and o=0, or m=0, n=1 and o=1.
[0038] In an embodiment, R.sup.a is H at each occurrence.
[0039] In an embodiment, R.sup.b is H at each occurrence.
[0040] In a further embodiment, R.sup.a is H, R.sup.b is H and m=0,
n=1 and o=0.
[0041] Aryl groups include aromatic ring systems comprising 6, 7,
8, 9, 10, 11, 12, 13, 14, 15 or 16 ring carbon atoms. Aryl groups
may consist of a single ring but may include a polycyclic ring
system, having two or more rings, at least one of which is
aromatic. Aryl groups include: phenyl, naphthyl, fluorenyl,
azulenyl, indenyl and anthryl groups.
[0042] In an embodiment, the aryl group is phenyl.
[0043] Heteroaryl groups include aromatic heterocyclic ring systems
having 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms with
1 to 4 heteroatoms independently selected from nitrogen, oxygen and
sulfur. The group may be a polycyclic ring system, having two or
more rings, at least one of which is aromatic, but is more often
monocyclic. Preferred heteroaryl groups are monocyclic groups
containing 5 or 6 ring atoms. Heteroaryl groups include: pyrrolyl,
pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl,
furyl, thiophenyl, pyridyl, pyrimidyl, benzimidazolyl, indolyl,
isoquinolyl, quinoxalinyl and quinolyl.
[0044] In an embodiment, the heteroaryl group is selected from the
group comprising: pyridine, pyrimidine, pyrazine, pyrazole, and
oxazole. Preferably the heteroaryl group is pyridine.
[0045] When one or more of the above groups is optionally
substituted, each optional substituent is preferably an
independently chosen halo atom. Amongst halo, chloro and fluoro are
preferred. Preferably, the halo atoms are the same when there are
more than one.
[0046] In an embodiment, R.sup.1 is C.sub.1-4alkyl, preferably
i-propyl, and R.sup.4 is optionally substituted aryl, preferably
4-fluorophenyl.
[0047] In another embodiment, R.sup.2 is --S(O).sub.2R.sup.9
wherein R.sup.9 is C.sub.1-6 alkyl, preferably methyl, and R.sup.3
is hydrogen or C.sub.1-6 alkyl, preferably methyl.
[0048] In an embodiment, R.sup.1 is C.sub.1-4alkyl, preferably
i-propyl; R.sup.2 is --S(O).sub.2R.sup.9 wherein R.sup.9 is
C.sub.1-6 alkyl, preferably methyl; R.sup.3 is hydrogen or
C.sub.1-6 alkyl, preferably methyl; and R.sup.4 is optionally
substituted aryl, preferably 4-fluorophenyl.
[0049] The relationship between the groups R.sup.5 and R.sup.6 is
important for the activity of the compounds. Thus both R.sup.5 and
R.sup.6 cannot be hydrogen. Similarly, when R.sup.5 is hydrogen,
R.sup.6 ideally should not be an unsubstituted C.sub.1-6 alkyl
group e.g. methyl, ethyl, iso-propyl or tert-butyl. In one
embodiment, R.sup.5 is not hydrogen. In one embodiment, R.sup.6 is
not hydrogen.
[0050] In another embodiment, R.sup.5 is hydrogen and R.sup.6 is an
optionally substituted aromatic group. In this embodiment,
preferably the aromatic group is substituted by between 1 and 5
substituents as recited above. Preferably, the aromatic group is
ortho and/or para substituted, preferably ortho and para
substituted with 2 or 3 substituents. Preferably the substituents
for the aromatic group are halogen (e.g. fluorine or chlorine).
Preferably the substituents for the aromatic group are C.sub.1-4
alkoxy (e.g. methoxy).
[0051] In another embodiment, R.sup.5 is hydrogen and R.sup.6 is a
C.sub.1-6 haloalkyl group. In this embodiment, the haloalkyl group
is preferably a chloroalkyl group. The haloalkyl group is
preferably haloethyl. A particularly preferred group is
--CH.sub.2CCl.sub.3.
[0052] In another embodiment, R.sup.5 is an optionally substituted
benzyl and R.sup.6 is an optionally substituted C.sub.1-6alkyl,
preferably methyl, propyl, isopropyl, butyl, isobutyl or tertbutyl.
In another embodiment, R.sup.5 is an optionally substituted benzyl
and R.sup.6 is an optionally substituted C.sub.2-6 alkenyl,
preferably propylene. In another embodiment, R.sup.5 is an
optionally substituted benzyl and R.sup.6 is a C.sub.1-6 haloalkyl,
preferably 2,2,2-trichlororethyl.
[0053] In another embodiment, R.sup.5 is a C.sub.1-6 alkanoyl
heteroaryl group and R.sup.6 is an optionally substituted
C.sub.1-6alkyl, preferably methyl, ethyl or propyl.
[0054] In an embodiment, the compound has a structure selected
from:
##STR00004## ##STR00005## ##STR00006##
[0055] As mentioned above, statins having an open, hydroxy acid
conformation are known to have an inhibitory effect on HMG-CoA
reductase. It is also known that the lactone, closed-ring analogue
of such hydroxy acids are inactive with respect to inhibiting
HMG-CoA reductase and that decyclisation of the lactone is
necessary to activate the lactone. However, we have found that
functionalised lactols of the present invention have a significant
inhibitory effect on HMG-CoA reductase in their own right. This is
surprising in view of the fact that these molecules are
conformationally constrained in ring closed form.
[0056] Examples of conditions that may be treated by the inhibition
of HMG-CoA reductase include hypercholesterolemia, atherosclerosis
and hyperlipidemia. Statins have been used in the secondary
prevention of cardiovascular disease, or in the primary prevention
of cardiovascular disease when the risk for cardiovascular disease
is significantly raised. It is therefore expected that the
compounds of the present invention will have utility in the
treatment or prevention of cardiovascular diseases due to their
inhibitory activity. Example cardiovascular diseases which may be
treatable by the compounds of the present invention include:
coronary heart disease, myocardial infarction, stroke and
peripheral artery disease. In addition, these compounds may also
have a beneficial effect in the treatment of inflammation,
dementia, cancer, nuclear cataracts, diabetes and hypertension.
[0057] The conditions that may be treated by the inhibition of
HMG-CoA reductase may be a condition of the human or animal body.
These compounds are intended in particular for human patients.
[0058] Processes for the manufacture of the compounds of the
present invention are disclosed in WO2005/092867, in particular, in
the examples. The disclosure of WO2005/092867 insofar as the
synthetic procedures are concerned forms part of the disclosure of
the present invention. In the interests of brevity, the details of
these synthetic procedures is not reproduced here but it is
intended that this subject matter is specifically incorporated into
the disclosure of this document by reference.
[0059] The present invention also includes the synthesis of all
pharmaceutically acceptable isotopically-labelled compounds of
formula (I) wherein one or more atoms are replaced by atoms having
the same atomic number, but an atomic mass or mass number different
from the atomic mass or mass number usually found in nature.
[0060] Examples of isotopes suitable for inclusion in the compounds
of the invention include isotopes of hydrogen, such as .sup.2H and
.sup.3H, carbon, such as .sup.11C, .sup.13C and .sup.14C, chlorine,
such as .sup.36Cl, fluorine, such as .sup.18F, iodine, such as
.sup.123I and .sup.125I, nitrogen, such as .sup.13N and .sup.15N,
oxygen, such as .sup.15O, .sup.17O and .sup.18O, phosphorus, such
as .sup.32P, and sulphur, such as .sup.35S.
[0061] Certain isotopically-labelled compounds, for example, those
incorporating a radioactive isotope, are useful in drug and/or
substrate tissue distribution studies. The radioactive isotopes
tritium, i.e. .sup.3H, and carbon-14, i.e. .sup.14C, are
particularly useful for this purpose in view of their ease of
incorporation and ready means of detection.
[0062] Substitution with heavier isotopes such as deuterium, i.e.
.sup.2H, may afford certain therapeutic advantages resulting from
greater metabolic stability, for example, increased in vivo
half-life or reduced dosage requirements, and hence may be
preferred in some circumstances.
[0063] Substitution with positron emitting isotopes, such as
.sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy.
[0064] Isotopically-labelled compounds can generally be prepared by
conventional techniques known to those skilled in the art or by
processes analogous to those described using an appropriate
isotopically-labelled reagent in place of the non-labelled reagent
previously employed.
[0065] Throughout the description and claims of this specification,
the words "comprise" and "contain" and variations of the words, for
example "comprising" and "comprises", means "including but not
limited to", and is not intended to (and does not) exclude other
moieties, additives, components, integers or steps.
[0066] Throughout the description and claims of this specification,
the singular encompasses the plural unless the context otherwise
requires. In particular, where the indefinite article is used, the
specification is to be understood as contemplating plurality as
well as singularity, unless the context requires otherwise.
[0067] Features, integers, characteristics, compounds, chemical
moieties or groups described in conjunction with a particular
aspect, embodiment or example of the invention are to be understood
to be applicable to any other aspect, embodiment or example
described herein unless incompatible therewith.
General Procedure
[0068] All assays were carried out in a reaction buffer containing
100 nM K.sub.xPO.sub.4 at pH 7.2, 1 mM EDTA, 500 mM KCl and 1 mg/ml
BSA. The concentrations of NADPH and HMG-CoA were both 200 .mu.M.
The enzyme concentration used is unknown although this
concentration is 10-fold lower than that of the stock solution
purchased. Inhibitors were dissolved in 75% DMSO. Where inhibitors
were found to be insoluble or only partly soluble in 75% DMSO, 100%
DMSO was used. Reactions were activated by the addition of enzyme
and agitated for 12 seconds following the addition. Absorbance
readings were then taken every 20 seconds for 600 seconds. In
initial tests the concentration of each inhibitor was set at 50 nM
to identify which compounds were the better inhibitors, compared to
the known Pravastatin inhibitor. After these were identified,
assays were carried out varying their concentrations from 0 nM to
50 nM allowing IC50 values to be calculated.
EXAMPLE 1
[0069] The following procedure was followed using a HMG-CoA
Reductase assay kit obtained from Sigma-Aldrich (catalogue number
CS1090). The assay is based on the spectrophotometric measurement
of the decrease in absorbance at 340 nm of NADPH in solution. A
decrease in absorbance is caused by the oxidation of NADPH by the
catalytic subunit of HMGR in the presence of the substrate HMG-CoA.
Effective inhibition of the HMG-CoA leads to a reduction in
oxidation of NADPH which in turn leads to a smaller reduction in
the absorbance at 340 nm over time. This is illustrated in the
following reaction scheme:
HMG-CoA+2NADPH+2H.sup.+.fwdarw.mevalonate+2NADP.sup.++CoA-SH
[0070] Compounds showing the best inhibitory action are those which
reduce the absorbance least.
Preparation of the Assay Solution
[0071] Ultrapure water (17 M.OMEGA.-cm or equivalent was used for
the preparation of reagents and throughout the procedure.
[0072] First, an assay buffer solution was prepared using the
following method: 0.2 ml of assay buffer, 5.times.(catalogue number
A5981) was diluted with 0.8 ml of ultrapure water. The resulting
buffer solution was kept on ice or stored at -20.degree. C. for
further use.
[0073] Next, 25 mg of NADPH (catalogue number N6505) was
reconstituted with 1.5 ml of the buffer solution. The reconstituted
NADPH was stored in working aliquots at -20.degree. C.
[0074] The HMG-CoA substrate solution (catalogue number S7447),
HMG-CoA reductase (catalogue number H8789) and inhibitor solution
(e.g. pravastatin, catalogue number I5909) were kept on ice
throughout the procedure.
1. Before beginning, the spectrophotometer was set at 37.degree. C.
and 340 nm, with a kinetic programme: 1 ml sample, read every 20
seconds for up to 10 minutes. 2. The appropriate volumes of the
reaction solutions were added according to Table 1 (1 ml
assay).
TABLE-US-00001 TABLE 1 Reaction volumes for 1 ml samples Test 1x
Assay compound/ Sample buffer Pravastatin NADPH HMG-CoA HGMG Blank
920 .mu.l -- 20 .mu.l 60 .mu.l -- Activity 915 .mu.l -- 20 .mu.l 60
.mu.l 5 .mu.l Inhibition 910 .mu.l 5 .mu.l 20 .mu.l 60 .mu.l 5
.mu.l
[0075] The reagents were added to the reaction in the following
order: [0076] a. Add a buffer to all samples. [0077] b. Add the
inhibitor (test compound/Pravastatin) to the inhibition sample.
[0078] c. Add the reconstituted NADPH to all samples. [0079] d. Add
Substrate Solution (HMG-CoA) to all samples. [0080] e. Add HMG-CoA
Reductase (HMGR) to the Activity and Inhibition samples. [0081] f.
Mix the samples thoroughly. 3. The kinetics programme was started
immediately. The activity of the product was calculated according
to the following equation:
[0081] Units / mgP = ( .DELTA. A 340 / min sample - .DELTA. A 340 /
min control ) .times. TV 12.44 .times. V .times. 0.6 .times. LP
##EQU00001##
where: 12.44=.epsilon..sup.mM--the extinction coefficient for NADPH
at 340 nm is 6.22 mM.sup.-1cm.sup.-1. 12.44 represents the 2 NADPH
consumed in the reaction. TV=total volume of the reaction in ml (1
ml for cuvettes) V=volume of enzyme used in the assay (ml)
0.6=enzyme concentration in mg-protein (mgP0/ml (0.55-0.65 mgP/ml)
LP=light path in cm (1 for cuvettes).
EXAMPLE 2
[0082] The following table provides IC50 values for particular
rosuvastatin compounds of the present invention.
TABLE-US-00002 IC.sub.50 Compound Structure (nM) Rosuvastatin
calcium salt 4 ##STR00007## <1 ##STR00008## 8 ##STR00009## 1
##STR00010## 22 ##STR00011## 4 ##STR00012## 3 ##STR00013## 2
##STR00014## 1 ##STR00015## 2 ##STR00016## 2 ##STR00017## 10
EXAMPLE 3
[0083] The following example demonstrates the efficacy of the
compounds of the invention. The Example demonstrates the effect of
3 or 5 days BID treatment with four rosuvastatin compounds of the
present invention and rosuvastatin (all at 25 mg/kg po) on rat
plasma triglyceride levels 16 hours after the last treatment dose.
The measurement of the change in rat plasma triglyceride levels is
considered to be a fair test for determining HMG CoA reductase
activity.
[0084] 112 male SD rats (Harlan) were housed in groups of 6 under a
12 h light dark cycle (lights on 07.00 h) with free access to food
(normal laboratory chow) and water. Animals between 148-183 g were
allocated to treatment groups of 8 balanced by body weight and
treatments were balanced across cages.
[0085] Four rosuvastatin analogues were made up in 10% PEG300/10%
cremophor/80% methyl cellulose (0.5%) (vehicle 1) to make a 5 mg/mL
solution. The rosuvastatin compounds used were:
Rosuvastatin Lactol n-propyl acetal (diastereomeric ratio 2/1)
(BPL001); Rosuvastatin lactol n-propyl acetal nicotinoyl ester
(diastereomeric ratio 2/1) (BPL002); Rosuvastatin lactol iso-propyl
acetal benzyl ether (BPL003); and Rosuvastatin lactol methyl acetal
nicotinoyl ester (diastereomeric ratio 2/1) (BPL004).
[0086] Rosuvastatin was formulated in 0.5% Tween in 0.5% methyl
cellulose (vehicle 2) at 5 mg/kg as a suspension.
[0087] Rats were orally dosed with vehicle 1, one of the four
rosuvastatin analogues in vehicle 1 (25 mg/kg), vehicle 2 or
rosuvastatin in vehicle 2 (25 mg/kg po), BID for 3 or 5 days.
[0088] Sixteen hours after the last treatment, terminal plasma
samples were taken, stored at -20.degree. C., and transported on
dry ice for analysis of triglyceride levels.
[0089] Data for each time-point were analysed by 1-way ANOVA and
post-hoc Dunnett's test.
[0090] The results are provided in FIG. 1 from which it can be
deduced that administration of rosuvastatin (25 mg/kg po) BID for 3
or 5 days causes a marked reduction in plasma triglycerides. All
four rosuvastatin analogues also significantly reduced plasma
triglycerides after both 3 and 5 days BID treatment. All animals
tolerated the rosuvastatin treatments well and there was no
evidence of any adverse events.
[0091] The magnitude of the effect of the rosuvastatin analogues
was equivalent to that of rosuvastatin.
* * * * *